Related Experiment Video
Updated: Jul 16, 2026
Strategies for Assessing Autistic-Like Behaviors in Mice
Published on: September 20, 2024
Toward a Therapy for Autism Spectrum Disorder: The Formyl Peptide Receptor 2 Agonist MR-39 Supports Synaptic Health
Daniele Vitone1, Fabio Francavilla1, Maria Grazia Ferraro2
1Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, via Orabona 4 70125, Bari, Italy.
Abstract:
Chronic unresolved inflammation is a common feature of several Central Nervous System (CNS) disorders, including autism spectrum disorder (ASD). We previously demonstrated that Formyl Peptide Receptor 2 (FPR2) activation by our agonist MR-39 reduced several inflammatory markers and improved social behavior in two validated animal models of ASD. Therefore, we decided to delve deeper into the potential of MR-39 as a drug for treating ASD. We first investigated the molecular mechanisms underlying the beneficial effects of MR-39 in BTBR mice. MR-39 significantly normalized pro-inflammatory cytokine release and NF-κB expression in the hippocampus and cortex, resulting in upregulation of synaptophysin protein levels, which, in turn, promote plasticity and correct abnormalities in dendritic spine morphology. Next, we characterized the safety and pharmacokinetic profile of MR-39 with respect to potential advancement for further pre- and clinical studies. We found that MR-39 was not genotoxic and safe to use since it had limited interaction with the majority of the targets associated with the adverse drug reaction. Consistently, a repeated-dose administration study evidenced no clinical signs attributable to treatment-related toxicity. On the other hand, MR-39 exhibited rapid hepatocyte clearance and interaction with efflux systems in vitro, suggesting possible limitations due to its pharmacokinetic properties. Finally, we explored multiple strategies to overcome MR-39's low aqueous solubility, finding that the cosolvent approach can greatly enhance solubility and wettability. Overall, our study confirmed that promoting inflammation resolution with MR-39 can open new therapeutic options for ASD and that this compound has potential as a drug.
Insights
MR-39, an agonist targeting Formyl Peptide Receptor 2 (FPR2), effectively reduced inflammation and improved social behaviors in autism spectrum disorder (ASD) models. Further studies confirmed its safety and potential therapeutic applications for ASD.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Chronic inflammation is implicated in Central Nervous System (CNS) disorders like autism spectrum disorder (ASD).
- Formyl Peptide Receptor 2 (FPR2) activation has shown potential in modulating inflammatory pathways relevant to ASD.
Purpose of the Study:
- To investigate the molecular mechanisms of MR-39's therapeutic effects in an ASD mouse model.
- To evaluate the safety and pharmacokinetic profile of MR-39 for potential clinical development.
- To explore strategies for improving MR-39's formulation and delivery.
Main Methods:
- MR-39's effects on pro-inflammatory cytokines and NF-κB expression were analyzed in the hippocampus and cortex of BTBR mice.
- Synaptophysin levels and dendritic spine morphology were assessed.
- Genotoxicity, safety pharmacology, and pharmacokinetic studies (in vitro and in vivo) were conducted.
- Solubility enhancement strategies, including the cosolvent approach, were investigated.
Main Results:
- MR-39 normalized cytokine release and NF-κB expression, leading to increased synaptophysin and corrected dendritic spine abnormalities.
- MR-39 demonstrated a favorable safety profile, with no genotoxicity and limited off-target interactions.
- Pharmacokinetic studies revealed rapid hepatocyte clearance and efflux system interactions, indicating potential limitations.
- The cosolvent approach significantly improved MR-39's solubility and wettability.
Conclusions:
- MR-39 effectively targets inflammatory pathways implicated in ASD, offering a potential therapeutic strategy.
- While MR-39 shows promise, its pharmacokinetic properties require further optimization for clinical application.
- Formulation strategies can overcome solubility challenges, supporting the development of MR-39 as an ASD therapeutic.
